ASUBIO PHARMA CO., LTD. | Access

COMPANY

80s Foundation
90s Satisfaction
00s Transition

Foundation

Boldly engaged with new trends and directions and cultivated our fundamental strengths.

1979	Foundation of Suntory Institute for Biomedical Research.
1980	Initiation of research work on Tetrahydrobiopterin, for treatment of genetic metabolic disease.
1981	Synthesis of α-neo-endorphin gene and production of this peptide using an E.coli expression system.
1981	Synthesis of SUNRYTHM.
1982	Production of recombinant human IFN-γthrough application of synthetic gene.
1983	Introduction of Computer Aided Drug-design System (SCADS).
1984	First to successfully perform genetic cloning for hANP
1985	Introduction of penem-type antibiotic FAROM through application of SCADS
1986	Establishment of production method for hANP using recombinant DNA technology.
1987	Cloning of a cDNA encoding C-terminal α-amidating enzyme.
1988	?????
1989	Establishment of commercially applicable production method for recombinant human calcitonin.

SatisfactionPage Top↑

Hard-earned abilities and skills began to blossom.

1991年	Launch of SUNRYTHM, an anti-arrhythmic agent. First drug developed in-house by Suntory and the first anti-arrhythmic agent originated in Japan.
	Establishment of production method for hCNP using recombinant DNA technology.
	Establishment of production method for recombinant human calcitonin using recombinant DNA technology.
1992	Acquisition of supplemental approval of conformity for "Sunrhythm Capsule", an antiarrhythmic agent for the treatment of supraventricular tachyarrhythmia.
	Launch of BIOPTEN (sapropterin hydrochloride), for the treatment of Tetrahydrobiopterin deficiency.
	Launch of BIOGAMMA, an anti-cancer agent.
1994	Synthesis of SUN N4057 for the treatment of acute stroke.
1995	Launch of HANP (human atrial natriuretic peptide) for acute heart failure.
	Received Nikkei Technology Award for "Establishment of commercially applicable production method for C-terminal amidated peptide usingα-amidating enzyme."
	Establishment of commercially applicable production method for human parathyroid hormone.
1997	Launch of "FAROM tablet".
1997	Establishment of production method for GLP-1 (anti-diabetes) using recombinant DNA technology.
1998	Synthesis of SUN N8075 for the treatment of acute stroke.
1999	Incorporation of Suntory Pharmaceuticals, Inc. (now Asubio Pharmaceuticals, Inc.) for clinical development outside Japan.
1999	Launch of the pediatrics formulation "FAROM Dry Syrup".

TransitionPage Top↑

Found a means of survival in unique R&D.

2000	Launch of parenteral formulation of SUNRYTHM, "SUNRYTHM Injection."
2002	Incorporation of Daiichi Suntory Pharma Co., Ltd.
2003	Establishment of production method for a growth hormone releasing peptide "Ghrelin"
2004	Development of "SUN13834", a candidate drug for the treatment of atopic dermatitis.
2004	License agreement with BioMarin Pharmaceutical Inc.of USA for the development of BIOPTEN for the treatment of PKU.
2005	Launch of Adenoscan®
	Change of the company name to Daiichi Asubio Pharma Co., Ltd and move of headquarter to Akasaka, Minato-Ku, Tokyo
	Completion of a new bio plant (facility no. 7) for the production of peptide drug entities in the BioPharma Center
2006	The new bio plant (facility no. 7) was selected as a finalist for the 2006 Facility of the Year (sponsored by the International Society for Pharmaceutical Engineering (ISPE) and others)
2007	Change of company name to Asubio Pharma Co., Ltd. on April 1.
2007	Approval and launch of congenital metabolic disease agent "sapropterin hydrochloride (Tetrahydrobiopterin)" in USA by the co-development partner company BioMarin Pharmaceutical (product name: KUVAN)
2008	Acquisition of approval for an additional indication of tetrahydrobiopterin-responsive hyperphenylalaninaemia (an orphan drug).
2008	Approval and launch of congenital metabolic disease agent “sapropterin hydrochloride (Tetrahydrobiopterin)” in Europe by MerckSerono S.A., a sales partner of BioMarin Pharmaceutical Inc. (product name: KUVAN)
2010	Reorganized as a new company ‘Asubio Pharma Co., Ltd.'
2010	Completion of the building for Head Office and Research Facility and relocation to kobe.
2011年	Approval and launch of "Memary (R) tablet", an NMDA receptor antagonism Alzheimer-type dementia therapeutic agent (right succeeded from Daiichi Sankyo Co., Ltd. in 2010).